Please wait a minute...

中国生物工程杂志

CHINA BIOTECHNOLOGY
中国生物工程杂志  2010, Vol. 30 Issue (03): 46-51    
研究报告     
多拉菌素产生菌aveD基因缺失突变株的构建
王洁颖1,2,甘邱锋2,3,张晓琳2**,汪洋2,宋渊4,路福平1
1.天津科技大学工业微生物教育部重点实验室 天津 300457
2.国家粮食局科学研究院 北京 100037
3.福建农林大学生物农药与化学生物学教育部重点实验室 福州 350002
4.中国农业大学生物学院微生物系 北京 100094
Deletion Analysis of aveD Gene from a Streptomyces avermitilis Mutant Producing Doramectin
1. Key Laboratory of Industrial Microbiology, Ministry of Education, Tianjin University of Science and Technology, Tianjin 300457, China
2.Academy of State Administration of Grain, Beijing 100037, China
3.Key Laboratory of Biopesticide and Chemical Biology, Ministry of Education,Fujian Agriculture and Forestry University, Fuzhou 350002, China
4.Department of Microbiology, College of Biological Sciences, China Agricultural University, Beijing 100094, China
 全文: PDF(1008 KB)   HTML
摘要:

阿维链霉菌(Streptomyces avermitilis)bkd76-3在发酵过程中添加环己羧酸(CHC)可产生抗寄生虫药物多拉菌素(doramectin,阿维菌素衍生物CHC-B1),但同时还产生其它三种无效组分CHC-B2、CHC-A1、CHC-A2。利用基因缺失载体pXJ04(pKC1139∷△aveD1+△aveD2)对该菌株的aveD基因进行缺失,获得的aveD缺失突变株经摇瓶发酵和HPLC检测,发现只存在2种产物,经LC/MS分析验证,这两种产物分别为CHC-B1和CHC-B2,表明该突变株完全丧失了合成CHC-A1和CHC-A2的能力。缺失突变株的CHC-B1产量较出发菌株提高了78.19%,CHC-B2的产量提高了602.3%,发酵产物中有效组分多拉菌素的比例增加了93.16%。该缺失突变是在染色体上通过同源双交换完成的,不会发生进一步的重组,因此突变株具有良好的遗传稳定性,在工业生产上具有应用价值。

关键词: 阿维链霉菌aveD基因缺失多拉菌素    
Abstract:

The avermectin analog doramectin(CHC-B1), sold commercially as DectomexTM, was co-produced with the undesired analog CHC-B2, CHC-A1 and CHC-A2 by Streptomyces avermitilis bkd76-3 with the supplementation of cyclohexanecarboxylic acid(CHC) during fermentation. Gene deletion vector pXJ04(pKC1139::△aveD1+△aveD2) was used to delete aveD gene in S.avermitilis bkd76-3. The aveD gene was displaced by deletion allele on the plasmid via double crossover. Shaking flask experiments and HPLC analysis showed that the aveD deletion mutant no longer produced the undesired analogue CHC-A1 and CHC-A2, and only made two components which were confirmed as CHC-B1 and CHC-B2 by LC/MS analysis. The yield of CHC-B1 improved 78.19%, and B2 improved 602.3%, the ratio of effective component had a 93.16% increase. The deletion mutant was proved to be genetically stable, and thus might be promising strain in industrial production of doramectin.

Key words: Streptomyces avermitilis    aveD    Gene deletion    Doramectin
收稿日期: 2009-11-26 出版日期: 2010-03-25
基金资助:

国家“863”计划(2006AA10A208)、“十一五”国家科技支撑计划(2006BAD08B02)资助项目

通讯作者: 张晓琳     E-mail: zxl@chinagrain.org
服务  
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章  
王洁颖
甘邱锋
张晓琳
汪洋
宋渊
路福平

引用本文:

王洁颖 甘邱锋 张晓琳 汪洋 宋渊 路福平. 多拉菌素产生菌aveD基因缺失突变株的构建[J]. 中国生物工程杂志, 2010, 30(03): 46-51.

WANG Ji-Ying, GAN Qiu-Feng, ZHANG Xiao-Lin, HONG Xiang, SONG Yuan, LU Fu-Beng. Deletion Analysis of aveD Gene from a Streptomyces avermitilis Mutant Producing Doramectin. China Biotechnology, 2010, 30(03): 46-51.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/        https://manu60.magtech.com.cn/biotech/CN/Y2010/V30/I03/46

[1] Burg R W, Miller B M, Baker E E, et al. Avermectins, new family of potent anthelmintic agents: producing organism and fermentation. Antimicrob Agents Chemother, 1979, 15(3): 361367. 
[2] Ikeda H, Omura S. Control of avermectin biosynthesis in Streptomyces avermitilis for the selective production of a useful component. J Antibiot, 1995, 48(7): 549562. 
[3] Ikeda H, Nonomiya T, Usami M, et al. Organization of the biosynthetic gene cluster for the polyketide anthelmintic macrolide avermectin in Streptomyces avermitilis. Proc Natl Acad Sci USA, 1999, 96(17): 95099514. 
[4] Ikeda H, Ishikawa J, Hanamoto A, et al. Complete genome sequence and comparative analysis of the industrial microorganism Streptomyces avermitilis. Nat Biotechnol, 2003, 21(5): 526531. 
[5] Denoya C D, Fedechko R W, Hafner E W, et al. A second branchedchain alphaketo acid dehydrogenase gene cluster(bkdFGH) from Streptomyces avermitilis: its relationship to avermectin biosynthesis and the construction of a bkdF mutant suitable for the production of novel antiparasitic avermectins. J Bacteriol, 1995, 177(12): 35043511. 
[6] 姜薇, 汪洋, 张晓琳, 等. 阿维菌素衍生物CHCB1的突变生物合成. 中国生物工程杂志, 2009, 29(8): 6874. Jiang W, Wang Y, Zhang X L, et al.China biotechnology, 2009, 29(8): 6874. 
[7] Cropp T A, Wilson D J, Reynolds K A. Identification of a cyclohexylcarbonyl CoA biosynthetic gene cluster and application in the production of doramectin. Nat Biotechnol, 2000, 18(9): 980983. 
[8] 房春林, 杨光有, 古小彬, 等. 多拉菌素的研究进展. 中国畜牧兽医, 2006, 33(5): 5557. Fang C L, Yang Y G, Gu X B, et al.China Anim Hus Vet Med, 2006, 33(5): 5557. 
[9] Ikeda H, Wang L R, Ohta T, et al. Cloning of the gene encoding avermectin B 5Omethyltransferase in avermectinproducing Streptomyces avermitilis. Gene, 1998, 206(2): 175180. 
[10] Bierman M, Logan R, O′Brien K, et al. Plasmid cloning vectors for the conjugal transfer of DNA from Escherichia coli to Streptomyces spp. Gene, 1992, 116(1): 4349. 
[11] Hanahan D. Studies on transformation of Escherichia coli with plasmids. J Mol Biol,1983, 166(4): 557580. 
[12] Sambrook J, Russell D. Molecular Cloning: A Laboratory Manual. 3rd ed. New York: Cold Spring Harbor Laboratory Press, 2001. 
[13] MacNeil D J, Klapko L M. Transformation of Streptomyces avermitilis by plasmid DNA.J Ind Microbiol, 1987, 2(4): 209218. 
[14] Ikeda H, Kotaki H, Tanaka H, et al. Involvement of glucose catabolism in avermectin production by Streptomyces avermitilis. Antimicrob Agents Chemother, 1988, 32(2): 282284. 
[15] Hopwood D A, Bibb M J, Chater K F, et al. Genetic manipulation of Streptomyces: A Laboratory Manual. Norwich: John Innes Foundation, 1985. 
[16] 姜薇. 多拉菌素的突变生物合成及发酵条件优化. 哈尔滨: 东北农业大学, 生命科学学院,2009. Jiang W. The mutational biosynthesis of doramectin and studies on the fermentation condition. Harbin: Northeast Agricultural University, College of life Sciences,2009. 
[17] 陈芝, 文莹, 宋渊, 等. 阿维链霉菌中aveD基因缺失对阿维菌素合成的影响. 微生物学报, 2002, 42(5): 534538. Chen Z, Wen Y, Song Y, et al.Acta Microbiol Sin, 2002, 42(5): 534538. 
[18] StutzmanEngwall K, Conlon S, Fedechko R, et al. Engineering the aveC gene to enhance the ratio of doramectin to its CHCB2 analogue produced in Streptomyces avermitilis. Biotechnol Bioeng, 2003, 82(3): 359369.

[1] 冯宝琪,冯娇,张苗,刘洋,曹睿,尹涵之,齐凤仙,李子龙,尹守亮. 利用Tn5型转座突变系统筛选高产阿维菌素菌株*[J]. 中国生物工程杂志, 2021, 41(7): 32-41.
[2] 李开秀,司维. 间充质干细胞来源的外泌体治疗炎症性肠病研究进展*[J]. 中国生物工程杂志, 2021, 41(7): 66-73.
[3] 葛伟峰, 储消和, 王永红, 张嗣良. 应用于二维电泳细胞蛋白质样品提取的复合蛋白酶抑制剂的优化[J]. 中国生物工程杂志, 2010, 30(12): 66-71.
[4] 龙宗娟 赵娇红 魏兰珍 王全喜 马为民. 利用同源重组构建蓝藻集胞藻6803ndhO基因突变株及其分子鉴定[J]. 中国生物工程杂志, 2010, 30(09): 31-35.
[5] 姜薇,汪洋,张晓琳,郭伟群,刘娣. 阿维菌素衍生物CHC-B1的突变生物合成[J]. 中国生物工程杂志, 2009, 29(08): 68-74.
[6] 柴建华. 人X染色体YAC图谱分析及DMD基因研究──在第二届联合国教科文组织南北人类基因组学术会议上的报告[J]. 中国生物工程杂志, 1995, 15(2): 8-10.